The Wnt/b-catenin pathway controls cell proliferation, death and differentiation. Several families of extracellular proteins can antagonize Wnt/b-catenin signaling, including the decoy receptors known as secreted frizzled related proteins (SFRPs), which have a cysteine-rich domain (CRD) structurally similar to the extracellular Wnt-binding domain of the frizzled receptors. SFRPs inhibit Wnt signaling by sequestering Wnts through the CRD or by forming inactive complexes with the frizzled receptors. Other endogenous molecules carrying frizzled CRDs inhibit Wnt signaling, such as V3Nter, which is proteolytically derived from the cell surface component collagen XVIII and contains a biologically active frizzled domain (FZC18) inhibiting in vivo cell proliferation and tumor growth in mice. We recently showed that FZC18 expressing cells deliver short-range signals to neighboring cells, decreasing their proliferation in vitro and in vivo through the Wnt/b-catenin signaling pathway. Here, using low concentrations of soluble FZC18 and Wnt3a, we show that they physically interact in a cell-free system. In addition, soluble FZC18 binds the frizzled 1 and 8 receptors' CRDs, reducing cell sensitivity to Wnt3a. Conversely, inhibition of Wnt/b-catenin signaling was partially rescued by the expression of full-length frizzled 1 and 8 receptors, but enhanced by the expression of a chimeric cell-membrane-tethered frizzled 8 CRD. Moreover, soluble, partially purified recombinant FZC18_CRD inhibited Wnt3a-induced b-catenin activation. Taken together, the data indicate that collagen XVIII-derived frizzled CRD shifts Wnt sensitivity of normal cells to a lower pitch and controls their growth. 
Introduction
The Wnt/b-catenin pathway controls cell fate through regulation of cell proliferation and death, migration, differentiation and metabolism [1] . Pathway activation involves interaction of Wnt ligands with cell surface Frizzled receptors and LRP5/6 co-receptors. This disrupts the Adenomatous polyposis coli (APC)-axin complex, thus halting proteasomal degradation of b-catenin, which is stabilized and interacts with T-cell factor (TCF) transcription factors, displacing repressors and recruiting activators of target gene expression.
The bioavailability of Wnts at the cell surface is regulated by several families of extracellular proteins. Heparan sulfate glycosaminoglycans control Wnt diffusion, thus enhancing interaction of Wnt ligands with Frizzled receptors [2] . Antagonists include members of the Dickkopf (DKK) family that block canonical signaling by binding to LRP5/6, thereby disrupting the Wntinduced Frizzled-LRP5/6 complex [3] . Wnt inhibitory factor-1 (WIF-1) binds directly to Wnts, altering their ability to interact with the receptors. The extracellular decoy receptors known as secreted frizzled-related proteins (SFRPs) have a frizzled cysteine-rich domain (CRD) structurally similar to the extracellular Wnt-binding domain of the frizzled receptors. Frizzled CRDs contain 10 cysteines at conserved positions, which form a highly conserved 3D structure, bind Wnts and form homodimers or heterodimers [4] . Thus, SFRPs can modulate Wnt signaling by sequestering Wnts through the CRD or by acting as dominant-negative inhibitors, forming inactive complexes with the frizzled receptors [5] . In addition, engineered SFRP-like proteins such as the soluble CRD of the receptor Frizzled 8 bind Wnt3a and inhibit autocrine Wnt signaling and tumor growth in mice carrying teratomas [6] .
In addition to SFRPs, other endogenous molecules carrying frizzled CRDs inhibit Wnt signaling. Among them, V3Nter is a cell surface polypeptide that inhibits tumor growth and switches off the b-catenin target gene expression signature in vivo [7, 8] . V3Nter is proteolytically derived from the cell surface extracellular matrix component collagen XVIII [7, 9, 10] and contains a biologically active frizzled domain (FZC18) ( Figure 1A ) [7] . The CRD in the FZC18 domain is highly conserved in frog, mouse and man, all 10 cysteines and the number and type of intervening amino-acids being fully conserved [9] . Indeed, we previously showed a 100% probability that the predicted 3D model of FZC18_CRD matches the 3D structure of mouse SFRP3 and FZD8 CRDs [7] . In human liver cancer, endogenous collagen XVIII is proteolyzed, releasing the FZC18 precursor V3Nter. We have shown that low FZC18 protein expression in liver cancer correlated with markers of high Wnt/b-catenin activity and vice versa [7] .
In this work, we show that low concentration soluble FZC18 interacts with Wnt3a and with the receptors FZD1 and FZD8 in a cell-free system. Consequently, FZC18 reduces cell sensitivity to Wnt3a and inhibits Wnt/b-catenin signaling. In line with these findings, FZC18 inhibitory effects were partially rescued by the expression of FZD1 and FZD8 receptors, but enhanced by expression of FZD8_CRD-GPI, a cell-membrane-tethered chimeric FZD8_CRD. Finally, we produced high-yield soluble recombinant human FZC18_CRD-Fc fusion protein, which inhibited Wnt3a-induced b-catenin activation in vitro.
Materials and Methods

cDNA Clones
Human Igk-FZC18-myc/pSecTag2 (carrying an Igk signal peptide) and mouse Wnt3a-V5/pCDNA3.1 mammalian expression vectors, Super8NTopflash and Super8NFopflash CRT reporters, Cyclin D1 promoter reporter D1D-944pXP2 and the normalization Renilla luciferase vector pGL4.70[hRluc] were previously described [7] . The episomal expression vector pCEP-PU was from T. Sasaki [11] . Igk-FZC18-myc was transferred from pSecTag2 to pCEP-PU by PCR synthesis of an 875-bp fragment carrying 59-NheI and 39-BamHI restriction sites in the forward and reverse primers, respectively. The PCR fragment was ligated into pCRII-Topo-TA (Invitrogen), excised and subcloned into pCEP-PU. Mouse FZD8_CRD-myc/pcDNA3, mFZD8_CRD-Fc/pRK5 [12] (Addgene plasmid 16689) and empty pRK5 plasmid were from X. He, mFZD8_CRD-myc-GPI was from J. Nathans [13] , mFZD8-myc receptor/pEF1A [14] was from R. Nusse, pEF1/myc-his was from Invitrogen and rat FZD1-myc (Addgene plasmid 16798) was from R. Moon. Human FZC18_CRD was PCR cloned into BamHI and KpnI in pIDZFc in frame with an Igk signal sequence and a C-terminal human IgG Fc tag for affinity purification. A thrombin cleavage site was included to allow removal of the Fc tag. The sequences of primers were: forward, 59-GGG GGA TCC GCC CTG CTC GGG GCT GAC-39; reverse #1, 59-GGG CTC GAG AGA TCC ACG CGG TAC CAG TGC AGC CGG CCC AAT GAG-39; reverse #2, 59-GGG CTC GAG TGC AGC CGG CCC AAT GAG-39. Constructs were stably transfected in DHFR-deficient CHO cells with Effectene transfection reagent (Qiagen), and clones selected in media containing G418 (500 mg/ml, Sigma) and lacking hypoxanthine and thymidine. All cDNAs were checked by automatic sequencing (Sequencing Facility, Rennes University Hospital, France).
Biological Activity of Soluble FZC18
Collection of conditioned media (CM) from parental L cells (control CM) and Wnt3a CM was performed as recommended by ATCC and by R. Nusse lab website. For other CM, HEK293 EBNA cells were seeded at 2.2610 6 cells/10 mm dishes and transfected with either FZC18-myc/pCEP-PU, mFZD8_CRD-myc/pcDNA3, mFZD8_CRD-Fc/pRK5 or with the respective empty vectors and, 24 hr later, fresh media were replaced by DMEM (4.5 g/l glucose) without phenol red or FCS (Invitrogen). Conditioned media were collected 48 hr later, centrifuged at 450 g and filtered (0.2 mm). To obtain recombinant FZC18_CRD, conditioned media from hFZC18_CRD-Fc clones were screened for protein expression by ELISA and positive clones were confirmed by Western blot analysis using anti-human IgG-Fc antibody. The positive clones were further adapted to CD OptiCHO medium supplemented with 8 mM L-Glutamine. hFZC18_CRD-Fc producing cells were seeded into spinner flasks at 2610 5 cells/ml and incubated at 37uC and 5% CO 2 with agitation at 80 rpm in humidified air for 10 days. The medium was collected, cleared by centrifugation, filtered (0.45 mm) and stored at 4uC until purification. The samples were loaded on a protein A column following equilibration with 20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5. The column was washed with the same buffer until effluent absorbance returned to baseline. The bound proteins were eluted with 20 mM sodium phosphate, 100 mM sodium citrate, pH 2.5 followed by rapid neutralization by adding 0.1 volume of 1 M Tris-hydrochloride, pH 9.0. The yield of the purified proteins was approximately 1,5 mg/l and purity was over 40%, as estimated by sandwich ELISA using anti-Fc antibody (Abcam AB1927) for capture and peroxidase-conjugated secondary antibody (Sigma A0170) for detection. Purified proteins were stored at 280uC until use.
Immunological Methods
Coimmunoprecipitations were done by incubating either FZC18-myc or FZD8_CRD-myc pre-cleared CM with recombinant mWnt3a (100 ng/ml; 2.7 nM) and either mouse anti-myc or mouse IgG 1 (Dako) on a rotary wheel at 4uC overnight. Then, protein G magnetic beads (New England Biolabs), saturated overnight in protein extracts from 293EBNA cells in RIPA buffer (TrisHCl 50 mM, pH 7.4; 1% Triton-X-100; 25 mM Hepes; 150 mM NaCl; 0.2% Sodium deoxycholate, 5 mM MgCl 2 ), were added to immunocomplexes and incubated at 4uC, for 3 hr. After washing in RIPA buffer, complexes were eluted in denaturing sample buffer, resolved by 10% PAGE-SDS and immunoblotted. For reverse coimmunoprecipitation experiments, either rabbit anti-mWnt3a (C64F2, Cell Signaling) or rabbit IgG (Dako) was incubated either with recombinant mWnt3a plus FZC18-myc CM or with recombinant mWnt3a plus FZD8_CRD-myc CM. Coimmunoprecipitation of FZC18-myc with either recombinant mFZD1_CRD-Fc (100 ng/ml) or mFZD8_CRD-Fc CM was done as described above, using protein G magnetic beads binding the Fc tags. Immunoblots were performed with mouse anti-myc (Invitrogen) and with monoclonal rat anti-FZD1_CRD or anti-FZD8_CRD antibodies (R&D). Signal from immunoblots was detected by enhanced chemiluminiscence, as described [7] .
Results
The frizzled domain of collagen XVIII inhibits cell proliferation and DNA synthesis
We produced zeocin-resistant mass cultures of 293T cells stably expressing FZC18 or empty vector. To avoid clonal variability, we expanded colonies showing different densities of FZC18 (+) cells ( Figure 1B ). As FZC18 locates preferentially at the cell surface [7] , cell permeabilization followed by immunocytochemistry allowed identification of all cells expressing the protein of interest, regardless of protein maturation. Thus, batch #1 showed a lower density of FZC18 (+) cells ( Figure 1B ) and lower FZC18 expression by immunoblot than batch #4 and #5 cells ( Figure 1C ). When passaged routinely, FZC18 (+) cells grew more slowly, formed smaller cell plates than vector cells and secreted soluble FZC18 ( Figure S1 , B and C). Simultaneous detection of N-and C-terminal epitopes in this fusion protein indicated preservation of FZC18 integrity in cells ( Figure 1C ) and in the medium ( Figure S1C ). An 8-day time course cell proliferation assay showed that FZC18-expressing cells grew more slowly than vector cells ( Figure 2A ).
3H
Thymidine incorporation rates into DNA showed that FZC18 reduces cell proliferation and DNA synthesis ( Figure 2B ). Throughout the 8-day cell proliferation assay, mitochondrial succinate dehydrogenase activity in living cells (MTT assay) confirmed the decrease in cell growth in FZC18-expressing cells ( Figure S2 ). The decrease in proliferation rates was correlated with the expression levels of FZC18 in the stable cell cultures ( Figure 1B ). No significant difference in spontaneous cell death was observed in these cells compared to vector-expressing cells by flow cytometry search for subG1, hypo-diploid cells (not shown).
FZC18 reduces cell sensitivity to soluble Wnt3a
Incubation of vector and FZC18-expressing 293T cells with conditioned medium (CM) from L cells secreting soluble Wnt3a (Wnt3a CM) confirmed that FZC18 reduces Wnt3a-induced Wnt signaling (Figure 3 ), b-catenin stabilization, cyclin D1 promoter activity and protein expression ( Figure S3 ). FZC18-expressing cells showed lower amounts of steady-state b-catenin protein ( Figure  S3A ) and cyclin D1 promoter activity than control cells ( Figure  S3B ). In particular, cyclin D1 protein expression in response to soluble Wnt3a was considerably stronger in vector cells than in FZC18 cells ( Figure S3C ), indicating that FZC18 abrogates the response to Wnt3a. The dose-response curve to different dilutions of Wnt3a CM showed that FZC18-expressing cells could efficiently build up a CRT response to Wnt3a, in such a way that the higher the concentration of Wnt3a CM, the higher the fold-change in CRT. However, the absolute CRT levels in FZC18-expressing cells were 5 to 8 folds lower than those in vector cells ( Figure S3D ). Figure S4 ). Likewise, it has been recently shown that in a normal cell context, different cell systems respond to Wnt stimulation with similar foldchange despite their different starting and output levels in Wnt/bcatenin signaling [15] . Thus, FZC18 may not impair downstream processing of Wnt stimuli, but it seems to decrease cell sensitivity to Wnt3a, probably by blocking Wnt access to frizzled receptors.
Soluble FZC18 binds Wnt3a
Co-expression of FZC18 and Wnt3a in non permeabilized AT3F1S315 mouse hepatoma cells [16] followed by confocal microscopy analysis revealed that both proteins colocalized at the cell surface, highlighting cell contacts ( Figure 4A ). We further confirmed that HEK293T cell clones stably expressed FZC18 at the cell surface by immunostaining with antibodies detecting the N-and C-termini of the FZC18-myc fusion protein ( Figure S5A ). Moreover, subcellular fractionation confirmed that FZC18 was exclusively detected in the crude membrane fraction ( Figure S5B ), indicating that the protein is indeed addressed to the secretory pathway.
Using protein extracts from cells cotransfected with both FZC18 and Wnt3a, we previously showed that these ectopically expressed molecules interact [7] . However, cysteine-rich proteins like Wnts and the Frizzled CRDs may get clogged within the secretory pathway [2] , leading to high intracellular concentration and spurious interactions. Here, we wished to study these interactions in a cell-free system, using soluble FZC18 and Wnt3a, at low concentrations. Despite easy detection of FZC18-myc by immunocytochemistry, immunoblot detection showed no signal in nonconcentrated CM, in contrast to FZD8_CRD-myc, which was detected at high levels ( Figure S5C ). Concentration of FZC18 CM by 13 folds was required to observe a detectable signal by immunoblot ( Figure S5C ). For coimmunoprecipitation, we added purified recombinant Wnt3a to non-concentrated FZC18-myc or FZD8_CRD-myc CM. Wnt3a concentration (2.7 nM) was within the physiological range [13, 17, 18, 19, 20] . Under these conditions, both FZC18-myc and FZD8_CRD-myc pulled down Wnt3a ( Figure 4B ). Accordingly, reverse co-immunoprecipitation revealed that Wnt3a pulled down both FZC18-myc and FZD8_CRD-myc ( Figure S5D ). Additionally, both precipitation and immunoblot with anti-myc antibody confirmed the presence of soluble FZC18 and FZD8_CRD at the expected amounts in these CM ( Figure  S5E ).
Extracellular FZC18 inhibits Wnt3a-induced Wnt/bcatenin signaling
We tested whether the CRD of FZC18 (FZC18_CRD) could effectively inhibit Wnt signaling. FZC18_CRD was cloned in frame with a human Igk signal sequence and a human Fc tag from IgG. Human FZC18_CRD-Fc preparations with 40% purity were tested for biological activity. As expected, hFZC18_CRD-Fc dosedependently inhibited Wnt3a-induced CRT ( Figure 5 ). Inclusion of a thrombin cleavage site did not significantly affect Wnt inhibitory activity of hFZC18_CRD-Fc ( Figure S6 ). Taken together, these findings support the concept that FZC18 exerts its biological effects in the extracellular compartment and that the CRD of FZC18 has Wnt inhibitory activity.
FZC18 seems to provide short-range signals, thus working as an SFRP-like molecule [8] . We thus confirmed whether FZC18-expressing cells impact on the microenvironment of adjacent cells and modulate their response to Wnt stimuli. FZC18-expressing Figure S7 ). Under these conditions, the response of the reporter cells to soluble Wnt3a was inversely proportional to the number of FZC18 (+) cells in the co-culture system. (Figures 6 and S8) , mouse FZD1 and Drosophila FZ3 may behave as antagonists of canonical Wnt/bcatenin signaling [21, 22] . Excessive ectopic stimulation of bcatenin signaling via frizzled receptors may result in saturation of the signal transduction capacity of pathway components downstream to the frizzled receptors. In keeping with this hypothesis, mouse wild-type FZD1 inhibits Wnt signaling less efficiently than does C-terminally deleted mouse FZD1 [21] . These data led us to test a hypothetical synergy between FZC18 and FZ CRDs, capable of binding Wnts but unable to transduce downstream signal.
Using FZC18-expressing cells, we compared the effects of the full-length FZD8 receptor, FZD8_CRD and a FZD8_CRD carrying a C-terminal glycosylphosphatidylinositol (GPI) anchor attaching the CRD at the cell surface (FZD8_CRD-GPI). Within the 10 pg-100 ng range of transfected cDNA, FZD8_CRD-GPI and FZD8_CRD further reduced Wnt signaling in FZC18-expressing cells ( Figure 6C ). Under the same conditions, fulllength FZD8 antagonized the effects of FZC18, increasing CRT ( Figure 6C) , supporting the data shown in Figure 6B . Effects of full-length FZD8 receptor, FZD8_CRD and FZD8_CRD-GPI on cells expressing the empty vector are provided on Figure S9 .
These results show an additive effect of FZC18 and either FZD8_CRD or FZD8_CRD-GPI, the dose-response curve outlining a higher efficacy of FZD8_CRD-GPI. Thus, Wnt/bcatenin signaling can be concomitantly downregulated by different Wnt-binding proteins. As FZD8_CRD is soluble, its cell surface bioavailability may thus be lower than that of FZD8_CRD-GPI, probably resulting in lower Wnt inhibitory activity.
Taken together, these data underline the specificity of the Wnt inhibitory activity of FZC18. As FZD receptors rescued Wnt/bcatenin signaling, but FZD CRDs further enhanced the inhibitory effects of FZC18, these findings indicate that the effects of FZC18 may not result from endoplasmic reticulum toxicity through clogging of the secretion pathway with cysteine-rich proteins.
FZC18 forms homodimers and binds the CRDs of FZD1 and FZD8 receptors
One of the well-known features of frizzled CRDs is their capacity to form homo and heterodimers [4] , conferring to SFRPs the ability to bind to frizzled receptor CRDs [5] . To investigate whether these features applied to FZC18, we cotransfected HEK293T cells with both V3Nter-V5 and FZC18-myc or with V2Nter-V5 and FZC18-myc ( Figure 7, A and B) . V3Nter is a precursor of FZC18 originated by endogenous proteolysis in human tissues [7] . V2Nter-V5 contains the same aminoterminal sequences of C18 as V3Nter, but lacks the FZC18 domain ( Figure 7A ). As both V2Nter and V3Nter share the DUF-959 domain, V2Nter was used as a negative control. Immunoprecipitation with anti-myc, followed by immunoblotting with anti-DUF-959 or with anti-V5 tag antibodies showed that FZC18 bound V3Nter but not V2Nter. This also excludes the possibility that FZC18 could bind other portions of the V3Nter molecule, such as the DUF-959 or the Tsp-1 domains ( Figure 7A ).
Next, we tested whether FZC18 could bind the CRDs of FZ receptors. To this end, we used soluble FZD1 or FZD8 CRDs fused to the Fc portion of human IgG ( Figure 7C ). Adding recombinant FZD1_CRD-Fc or FZD8_CRD-Fc CM to nonconcentrated FZC18 CM and immunoprecipitating with protein G coated beads, followed by immunobloting with anti-myc antibody showed that FZC18 could bind FZD1 and FZD8 CRDs. Taken together, the results suggest a model whereby FZC18 could bind both Wnts and FZD CRDs, hampering access of Wnts to the FZD receptors, thus blocking Wnt/b-catenin pathway activation in an SFRP-like mode (Figure 8 ).
Discussion
The microenvironment impacts Wnt activity and regulates cell behavior through extracellular molecules that fine tune the response to Wnt stimuli [5, 23] . Proteolysis in human tissues releases active FZC18 and tumors containing high levels of FZC18 show low b-catenin activation levels [7] . FZC18 behaves as an SFRP-like molecule inhibiting in vivo cell proliferation and tumor growth [8] . Although Wnt3a and FZC18 were shown to interact in a cell overexpression system [7] , whether the interaction was still active in a cell-free system at physiological concentrations remained unknown. Here, we show that soluble FZC18 binds Wnt3a and the receptors FZD1 and FZD8, and reduces cell sensitivity to Wnt3a. FZC18 inhibitory effects are partially rescued by FZD1 and FZD8 receptors, but enhanced by FZD8_CRD-GPI, a cell-surface-tethered FZD8_CRD chimera. Altogether, the results suggest that FZC18 shifts the sensitivity of cells to Wnt stimuli to a lower pitch, slowing their growth rate.
Although the concentration of soluble FZC18 in the conditioned medium was several fold lower than that of FZD8_CRD, a well-known partner of Wnt3a [6] , Wnt3a was efficiently pulled down by FZC18. Accordingly, Wnts bind to FZD CRDs with affinities lower than 90 nM [13, 17, 18, 19, 20] . In the present report, the use of soluble FZC18 at very low concentrations and a Wnt3a concentration within the physiological range (2.7 nM) indicates that spurious interactions of highly concentrated cysteine-rich proteins are unlikely. In addition, we show that FZC18 binds FZD1 and FZD8 CRDs, implying that FZC18 could form nonfunctional complexes with the frizzled receptors, thus acting as a dominant negative inhibitor of Wnt signaling. The major technical hardship of this work was the low yield of soluble FZC18. Expression of FZC18 using different vectors and mammalian host cell systems, allowing either genomic DNA integration or high copy number episomal replication of target sequences yielded low amounts of soluble FZC18 (not shown). Similarly, generation of isogenic stable mammalian cell lines using Flp recombinase and optimal site-specific genomic recombination failed to increase the yield of soluble FZC18 (not shown). Since we demonstrated that the CRD of FZC18 can form homodimers, we hypothesized that homodimerization could increase yield of soluble protein and expressed human FZC18_CRD sequences in frame with the Fc fragment of IgG in CHO cells. This vector/host combination dramatically increased yield of soluble FZC18_CRD in the medium. Furthermore, partially purified recombinant hFZC18_CRD-Fc inhibited Wnt/b-catenin signaling induced by soluble Wnt3a, confirming that the Wnt inhibitory activity resides within the frizzled CRD of FZC18.
Overexpression of either FZD1 or FZD8 receptors partially rescued Wnt signaling in FZC18-expressing cells. On the other hand, FZD8_CRD-GPI, which remains tethered to the cell surface, enhanced the inhibitory effect of FZC18 more efficiently than FZD8_CRD did, which freely diffuses into the medium. Therefore, competing CRDs may diminish sensitivity to Wnt ligands at the cell surface. Accordingly, recent evidence indicates that FZD receptors may be limiting partners in Wnt signal reception because decreased Wnt/Wg signaling resulting from ubiquitylation of FZD receptors can be rescued by FZD receptor overexpression [24] .
Finally, Wnt signaling outputs rely not only on ligand and receptor availability at the cell surface, but also on the microenvironment that can either enhance (such as heparan sulfate proteoglycans) [2] or blur (such as SFRPs, DKKs or FZC18) ligand/receptor interactions. In normal adult human tissues, FZC18 is released by stepwise proteolytic cleavage from a cell surface variant of collagen XVIII [9] [7] which is expressed at low levels. Its expression is up-regulated in liver fibrosis and in small, well-differentiated tumors, but decreases in advanced human liver cancers. Indeed, low FZC18 immunostaining in liver cancers correlates with markers of high Wnt/b-catenin activity [7] . Since the release of biologically active FZC18 is controlled by so far unidentified proteases, it is possible that cell growth or tumor invasion facilitate the local release of FZC18, conveying negative feedback cues to control cell fate. Therefore, further work is necessary to determine if FZC18 works as a cell surface sensor of proteolysis.
Ectopically expressed FZC18 blocks Wnt signaling in an SFRPlike fashion, inhibiting in vivo cell proliferation and tumor growth through paracrine signals [8] . However, further work will be necessary to know whether soluble FZC18 inhibits cell proliferation and tumor growth in vivo. The present work suggests that soluble FZC18 decreases cell sensitivity to Wnt signals by binding Wnt3a and the receptors Frizzled 1 and 8. Thus, the full repertoire of Wnt ligands and frizzled receptors that interact with FZC18 should be defined, as well as its possible interaction with other molecules of the extracellular matrix. In particular, FZC18 could signal through the non-canonical Wnt pathway to decrease cell 
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